Опыт неоадьювантной лекарственной терапии Her2-позитивного рака молочной железы

Л. В. Болотина, А. Л. Корниецкая, Дешкина Татьяна Игоревна · CyberLeninK (CyberLeninka) · 2016

Overexpression or amplification of human epidermal growth factor-2 receptor (HER2) occurs in approximately 20% of human breast cancers and has been traditionally associated with poor prognosis. Addition of trastuzumab to neoadjuvant chemotherapy for HER2-positive breast cancer improved the probability of achieving pathologically complete response and improves the long-term outcomes. Thus, patients with trastuzumab-treated HER2-positive breast cancer have the better prognosis that is compared to patients with HER2-negative breast cancer.

Cited by 0 works.

Authors